Arvinas Inc (ARVN)vsMerck & Company Inc (MRK)
ARVN
Arvinas Inc
$7.90
+3.95%
HEALTHCARE · Cap: $468.42M
MRK
Merck & Company Inc
$146.35
+3.83%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 20920% more annual revenue ($66.57B vs $316.70M). MRK leads profitability with a 4.8% profit margin vs 2.9%. ARVN trades at a lower P/E of 27.9x. ARVN earns a higher WallStSmart Score of 59/100 (C).
ARVN
Buy59
out of 100
Grade: C
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARVN.
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 66.4%
Revenue surging 1015.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Moderate valuation
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 1.6% — below average capital efficiency
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ARVN
The strongest argument for ARVN centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 1015.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : ARVN
The primary concerns for ARVN are P/E Ratio, EPS Growth, Market Cap. Thin 2.9% margins leave little buffer for downturns.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ARVN profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
ARVN carries more volatility with a beta of 1.81 — expect wider price swings.
ARVN is growing revenue faster at 1015.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
ARVN scores higher overall (59/100 vs 36/100) and 1015.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arvinas Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?